HC Wainwright reaffirmed their buy rating on shares of Synlogic (NASDAQ:SYBX) in a research note issued to investors on Monday morning, AnalystRatings.com reports. The firm currently has a $13.00 price objective on the biotechnology company’s stock.
SYBX has been the subject of several other research reports. ValuEngine raised shares of Synlogic from a hold rating to a buy rating in a research report on Friday, January 3rd. Zacks Investment Research cut shares of Synlogic from a strong-buy rating to a hold rating in a research report on Thursday, March 19th. Finally, Oppenheimer reaffirmed a hold rating on shares of Synlogic in a research report on Thursday, March 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $12.43.
SYBX stock traded up $0.05 during mid-day trading on Monday, reaching $2.01. The company had a trading volume of 116,900 shares, compared to its average volume of 470,051. The company has a debt-to-equity ratio of 0.15, a current ratio of 15.03 and a quick ratio of 15.03. The company has a market capitalization of $62.89 million, a PE ratio of -1.17 and a beta of 2.54. The firm has a 50 day moving average of $2.18 and a 200 day moving average of $2.33. Synlogic has a 12 month low of $1.35 and a 12 month high of $10.01.
A number of large investors have recently bought and sold shares of SYBX. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Synlogic during the fourth quarter valued at approximately $37,000. Virtu Financial LLC purchased a new stake in Synlogic during the fourth quarter valued at approximately $48,000. UBS Group AG lifted its position in Synlogic by 67.2% during the fourth quarter. UBS Group AG now owns 21,828 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 8,770 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Synlogic by 42.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 31,856 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 9,553 shares during the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Synlogic during the fourth quarter valued at approximately $197,000. 51.35% of the stock is owned by institutional investors.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.